TILs are expanded from resected tumor tissue ex vivo using IL-2, and once a patient has received lympho-depleting chemotherapy, the TILs are re-infused into the patient, followed by a systemic application of high-dose IL-2 [87]. Here, IL2 is linked to neoplasm.